中华医学杂志
2020年 · 第100卷第35期
中华医学杂志
中国阿尔茨海默病一级预防指南
Alzheimer's disease (AD) is the most common type of senile dementia, characterized by progressive neurological degeneration, and is an important cause of disability in the elderly[
中国老年患者围手术期麻醉管理指导意见(2020版)(四)
The list of members of the expert group for the formulation of this consensus:
抗N-甲基-D-天冬氨酸受体脑炎精神症状特征及照料者负担
机器人辅助下的骶髂螺钉置入精准性的临床分析
经皮冠状动脉介入治疗对不同左室射血分数的低危SYNTAX评分缺血性心肌病患者心功能的影响
重楼皂苷Ⅱ对胶质瘤增殖、侵袭和替莫唑胺化疗敏感性的影响
黄连素对脓毒症大鼠心肌损伤和心功能的保护作用及机制
亚低温治疗对猪心肺复苏后肝损伤的保护作用及机制
成人型神经元核内包涵体病脑磁共振成像表现分析
家族系肝豆状核变性ATP7B16、20号外显子突变二例
卡泊芬净单药治疗非人类免疫缺陷病毒感染肺孢子菌肺炎一例
核苷(酸)类似物长期治疗对慢性乙型肝炎患者肾脏的影响及其机制探讨
外周血神经源性外泌体突触蛋白提前5~7年预测阿尔茨海默病
Alzheimer's disease (AD) has become one of the diseases that seriously endanger the health and quality of life of the elderly worldwide. However, there is no effective drug that can cure AD at present. The main reason for the failure of previous AD drugs in clinical trials may be that the subject's disease course is already at a late stage. If there are biomarkers that can predict AD in the early onset or even asymptomatic stage of AD patients, and then intervene in patients, the appearance of clinical symptoms of patients may be delayed, thus improving the current treatment dilemma of AD. To this end, the research team recruited subjects from a longitudinal study 10 years ago to explore biomarkers for early diagnosis of AD. A total of 739 subjects were enrolled and divided into two stages: discovery and validation of exosomal synaptic proteins and establishment and validation of predictive models. During the discovery and validation stages, exosomal synaptic growth-associated protein 43 (GAP43), Neurogranin, synaptosome-associated protein 25 (SNAP25) and Synaptotagmin 1 in AD and mild cognitive impairment (MCI) subjects were significantly lower than those in the control group (P<0.001), exosomal biomarker levels correlated with levels in CSF (R2=0.54~0.70)。 In order to further verify the predictive ability of these exosomal synaptic proteins on the asymptomatic phase of AD, the team established a predictive model for the population of subjects with normal cognitive function 5 to 7 years ago and now developed AD, and predicted the incidence of this population. Subsequently, the predictive model was further validated in the familial AD cohort. Through ROC curve and ridge regression analysis, exosomal biomarkers had high efficacy to reflect brain pathological changes (AUCs =0.87-0.89), and could detect AD 5-7 years before cognitive impairment.
本期目次

